SCHEMBL4313440

SCHEMBL4313440

O=C(O)c1ccccc1/C=C/c1n[nH]c2ccccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 9/20 0.47
KDR P35968 7/20 0.47
MAP2K4 P45985 3/20 0.47
MAPK6 Q16659 2/20 0.47
CDK4 P11802 2/20 0.47
FLT3 P36888 2/20 0.47
AURKA O14965 2/20 0.47
FGFR1 P11362 2/20 0.47
TTK P33981 2/20 0.47
MAPK10 P53779 2/20 0.47
BMPR1B O00238 1/20 0.47
PLK4 O00444 1/20 0.47
STK25 O00506 1/20 0.47
CIT O14578 1/20 0.47
RIOK3 O14730 1/20 0.47
IKBKB O14920 1/20 0.47
GAK O14976 1/20 0.47
DCLK1 O15075 1/20 0.47
CHUK O15111 1/20 0.47
MUSK O15146 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4313444 1.00 CHEK1 (0.47) CHEK1KDRMAP2K4MAPK6CDK4
SCHEMBL4308053 0.84 FLT3 (0.58) KDRFLT3FGFR1JAK2LCK
SCHEMBL4308050 0.84 FLT3 (0.58) KDRFLT3FGFR1JAK2LCK
SCHEMBL4314918 0.79 CHEK1 (0.42) CHEK1KDRMAP2K4MAPK6CDK4
SCHEMBL4322099 0.78 CA1 (0.46) KDRFLT3AURKAFGFR1TTK
SCHEMBL4322095 0.78 CA1 (0.46) KDRFLT3AURKAFGFR1TTK
SCHEMBL300191 0.78 CHEK1 (0.48) CHEK1KDRMAP2K4MAPK6CDK4
SCHEMBL2945140 0.78 CHEK1 (0.48) CHEK1KDRMAP2K4MAPK6CDK4
SCHEMBL1597267 0.78 KDR (0.65) CHEK1KDRMAP2K4MAPK6CDK4
SCHEMBL1597265 0.78 KDR (0.65) CHEK1KDRMAP2K4MAPK6CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101111483-B IGF-1R inhibitors KYOWA HAKKO KIRIN CO.,LTD. (JP) 2011-12-14 CN disclosed
US-7605272-B2 IGF-1R inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-10-20 US disclosed
US-7605272-B2 IGF-1R inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-10-20 US disclosed
US-20090054508-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 US disclosed
US-20090054508-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 US disclosed
CN-101111483-A IGF-1R inhibitors KYOWA HAKKO KOGYO KK (JP) 2008-01-23 CN disclosed
EP-1847532-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-10-24 EP disclosed
EP-1847532-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-10-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054508-A1 IGF-1R INHIBITOR IGF1R, IGFBP5, IGFBP1 CHEK1 3274/4885KDR 75/4885MAP2K4 1642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.